When Ken Song was getting ready to leave his job as the CEO of a small biotech in 2020, he wasn’t sure what was next. But he knew one thing.
“I deliberately said I’m not going to do oncology. Oncology is so crowded. Everybody thinks they have the solution, but the reality is, it’s all noise,” he said.
That was until late March 2020, when he received two phone calls from two different investors, both pondering about the same thing: Was it possible to make more effective and widely applicable treatments that drop toxic radiation specifically to cancer cells, decimating them on site?